ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
대동맥류 스텐트 이식편 시장 규모는 2024년부터 2030년까지의 예측 기간 동안 CAGR 5.71%로 성장할 것으로 예측됩니다.
대동맥류 스텐트 이식편 시장은 당뇨병을 포함한 생활 습관병의 유병률 증가, 노인 인구 증가, 혁신적인 제품 개발 활동, 낮은 침습 절차 채택 증가 등으로 인해 상당한 성장을 보이고 있습니다.
대동맥류 스텐트 이식편 : 시장 역학
International Diabetes Federation 데이터(2022)에 따르면 20세에서 79세의 성인 5억 3,700만명이 당뇨병을 앓고 있으며, 이는 약 10명 중 1명에 해당합니다. 또한 2045년에는 7억 8,300만명에 달할 것으로 예상되고 있습니다. 5억 4,100만명의 성인이 2형 당뇨병의 발병 리스크가 높은 내당능 장애를 가지고 있습니다. 이 고위험군에서 낮은 침습 동맥류 관리를 위해 스텐트 이식편의 사용을 늘려야 하고 대동맥류 스텐트 이식편 장치에 대한 수요가 증가하고 있습니다.
제품별로 복부 대동맥 스텐트 이식편 부문은 2023년에 큰 수익 점유율을 차지할 것으로 예상됩니다.
복부 대동맥 스텐트 이식편은 복부 대동맥류 치료 전용으로 설계된 혈관 내 장치로 개복 수술없이 동맥류 수리를 용이하게합니다. 폴리테트라 플루오로에틸렌 등 생체 적합성과 내구성이 뛰어난 소재 사용되고 있습니다. 이 기구는 구조적 무결성을 제공하고 혈관의 리모델링을 촉진합니다. 신장 동맥이나 장골 동맥 부근의 복잡한 동맥류를 포함한 환자에 대한 울타리와 분기 부분 등이 있습니다.
이들은 특히 합병증이 있는 환자나 개복 수술의 위험이 높다고 생각되는 환자에서 널리 임상적으로 채용되고 있습니다. 설비의 맞춤화에 있어서 지속적인 개발에 박차를 가해 맞춤형의 혈관내 솔루션을 통해 환자의 결과를 개선하고 있습니다.
지역별로는 북미가 2023년 시장을 독점했으며 예측 기간 동안도 마찬가지라고 전망되고 있습니다. 진보, 시장의 주요 기업의 존재, 확립된 고급 의료 인프라의 가용성 등 몇 가지 요인이 기여하고 있습니다.
이 보고서는 세계 대동맥류 스텐트 그래프트 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 대동맥류 스텐트 그래프트 시장 보고서 : 인트로덕션
조사 범위
시장 분류
시장의 상정
제2장 대동맥류 스텐트 그래프트 시장 : 주요 요약
시장 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 대동맥류 스텐트 그래프트 시장 : 주요 요인 분석
시장 성장 촉진요인
생활습관병 증가
제품 개발 활동의 활성화
낮은 침습 수술에 대한 관심 증가
고령화 인구 증가
시장 성장 억제요인과 과제
대동맥류 스텐트 이식편 장치와 관련된 합병증
시장 기회
생체 적합성과 내구성이 뛰어난 재료의 개발
세계 및 지역 제조업체에 의한 전략적인 사업 활동
제6장 대동맥류 스텐트 그래프트 시장 : Porter's Five Forces 분석
제7장 대동맥류 스텐트 그래프트 시장 평가
제품별
복부 대동맥 스텐트 이식편
흉부 대동맥 스텐트 이식편
최종 사용자별
병원
외래수술센터(ASC)
기타
지역별
북미
유럽
아시아태평양
기타 지역
제8장 대동맥류 스텐트 그래프트 시장 : 기업 및 제품 프로파일
Medtronic
Terumo Corporation
Microport Scientific Corporation
Cook
Cordis
WL Gore & Associates, Inc.
Endologix LLC
SB-KAWASUMI LABORATORIES, INC.
Endospan
Lombard Medical
제9장 KOL의 견해
제10장 프로젝트 접근법
제11장 DelveInsight 정보
제12장 면책사항 및 문의
JHS
영문 목차
영문목차
Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of lifestyle disorders and the rising product developmental activities worldwide
The aortic aneurysm stent grafts devices market is growing at a CAGR of 5.71% during the forecast period from 2024 to 2030. The aortic aneurysm stent grafts devices market is observing substantial market growth primarily owing to the increasing prevalence of lifestyle disorders including diabetes, the rising geriatric population, innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive procedures that are expected to escalate the overall growth of the aortic aneurysm stent grafts devices market during the forecast period from 2024 to 2030.
According to data from the International Diabetes Federation (2022), in 2021, 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance, putting them at elevated risk for developing type 2 diabetes. Diabetes-related hypertension, atherosclerosis, and obesity elevate aneurysm risks, necessitating increased use of stent grafts for minimally invasive aneurysm management in this high-risk group, there is a growing demand for aortic aneurysm stent grafts devices.
Increased product developmental activities by the regulatory bodies worldwide are also slated to witness market growth for aortic aneurysm stent graft devices. For example, in June 2023, Cook Medical received FDA approval to initiate an investigational device exemption (IDE) study for an aortic aneurysm treatment. The study will evaluate the Zenith Fenestrated+ Endovascular Graft (ZFEN+).
Therefore, all the factors stated above collectively will drive the overall aortic aneurysm stent grafts devices market growth.
However, complications associated with aortic aneurysm stent grafts devices, and others may prove to be challenging factors for the aortic aneurysm stent grafts devices market growth.
Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of aortic aneurysm stent graft devices, the abdominal aortic stent graft category is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various key features of abdominal aortic stent grafts that enhance their utility and effectiveness.
Abdominal aortic stent grafts are endovascular devices designed specifically for the treatment of abdominal aortic aneurysms, facilitating aneurysm repair without open surgery. Constructed from biocompatible, durable materials like nitinol or stainless steel for the stent frame and woven polyester or polytetrafluoroethylene. These devices provide structural integrity and promote vascular remodeling. Key features include self-expanding or balloon-expandable designs, advanced anchoring mechanisms to prevent migration, and fenestrations or branches for cases involving complex aneurysms near renal or iliac arteries.
These have achieved widespread clinical adoption, particularly in cases where patients present with comorbidities or are considered at high-risk for open surgery. The success of abdominal aortic stent grafts in reducing aneurysm-related mortality also have spurred continued development in device customization, addressing variable aortic anatomies and improving patient outcomes through tailored endovascular solutions.
Additionally, in August 2024, Terumo India, announced the launch of the TREO Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO(R) Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation.
Therefore, the widespread uses and various key features of abdominal aortic stent graft that enhance performance and usability coupled with introduction of new and innovative products are solidifying the impact on the growth of the overall abdominal aortic stent graft devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall aortic aneurysm stent grafts devices market:
Among all the regions, North America is expected to dominate the aortic aneurysm stent grafts devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of diabetes, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure are acting as key factors contributing to the growth of the aortic aneurysm stent grafts devices market in the North America region during the forecast period from 2024 to 2030.
As per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, 38.4 million people of all ages, or 11.6% of the US population had diabetes. The rising diabetic population is expanding demand for aortic aneurysm stent grafts, as diabetes heightens vascular complications, weakening the aortic wall. Diabetic patients' higher surgical risk makes minimally invasive stent grafts a preferred intervention, driving market growth in aneurysm management.
Product developmental activities initiated by regulatory bodies and key manufacturers will further boost the market for aortic aneurysm stent grafts devices. For example, in May 2021, Endologix LLC, a leader in the treatment of vascular disease, announced the first implant of its ALTO(R) Abdominal Stent Graft in Canada following recent approval from Health Canada.
Additionally, in August 2021, Terumo Aortic announced that the US Food and Drug Administration (FDA) granted approval of its RelayPro thoracic stent-graft system for sale in the USA for the treatment of patients with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAUs).
The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional aortic aneurysm stent grafts devices market growth. The presence of key players such as Cook, Medtronic, and Cordis, with their strong distribution networks, ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American aortic aneurysm stent grafts devices market.
Some of the key market players operating in the aortic aneurysm stent graft devices market include Medtronic, Terumo Corporation, Microport Scientific Corporation, Cook, Cordis, W. L. Gore & Associates, Inc., Endologix LLC, SB-KAWASUMI LABORATORIES, INC., Endospan, Lombard Medical, and others.
Recent Developmental Activities in the Aortic Aneurysm Stent Grafts Devices Market:
In June 2024, Medtronic launched the Steerant Aortic Guidewire, tailored to facilitate catheter placement and exchange during diagnostic or interventional procedures in the aorta.
In January 2023, Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized controlled trial of two leading aortic stent graft systems, the Endurant II/IIs stent graft system, and GORE Excluder AAA Device Family systems.
In September 2022, Getinge joined forces with Medtronic to launch Radiant stent for ChEVAR procedures in Europe. The first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR). This new balloon-expandable stent graft for renal arteries obtained CE mark approval in September 2022.
Key Takeaways from the Aortic Aneurysm Stent Grafts Devices Market Report Study
Market size analysis for current aortic aneurysm stent grafts devices market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the aortic aneurysm stent grafts devices market.
Various opportunities available for the other competitors in the aortic aneurysm stent grafts devices market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current aortic aneurysm stent grafts devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for aortic aneurysm stent grafts devices market growth in the coming future?
Target Audience who can be benefited from this Aortic Aneurysm Stent Grafts Devices Market Report Study
Aortic aneurysm stent grafts devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in aortic aneurysm stent grafts devices
Various end-users who want to know more about the aortic aneurysm stent grafts devices market and the latest technological developments in the aortic aneurysm stent grafts devices market
Frequently Asked Questions for the Aortic Aneurysm Stent Grafts Devices Market:
1. What are aortic aneurysm stent grafts devices?
The aortic aneurysm stent grafts are devices placed inside the abdominal aorta or thoracic aorta to help protect the aneurysm from rupturing. The stent graft is placed inside the aneurysm with the help of a long, very thin, soft, plastic tube called a delivery catheter.
2. What is the market for aortic aneurysm stent grafts devices?
The aortic aneurysm stent grafts devices market is growing at a CAGR of 5.71% during the forecast period from 2024 to 2030.
3. What are the drivers for the aortic aneurysm stent grafts devices market?
The aortic aneurysm stent grafts devices market is observing substantial market growth primarily owing to the increasing prevalence of lifestyle disorders including diabetes, the rising geriatric population, innovative product developmental activities by the regulatory bodies, and the rising adoption of minimally invasive procedures that are expected to escalate the overall growth of the aortic aneurysm stent grafts devices market during the forecast period from 2024 to 2030.
4. Who are the key players operating in the aortic aneurysm stent grafts devices market?
Some of the key market players operating in aortic aneurysm stent grafts devices include Medtronic, Terumo Corporation, Microport Scientific Corporation, Cook, Cordis, W. L. Gore & Associates, Inc., Endologix LLC, SB-KAWASUMI LABORATORIES, INC., Endospan, Lombard Medical, and others.
5. Which region has the highest share in the aortic aneurysm stent grafts devices market?
North America is expected to dominate the overall Aortic Aneurysm Stent Grafts Devices market during the forecast period from 2024 to 2030. This can be attributed to several factors including the high instances of diabetes, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure are acting as key factors contributing to the growth of the aortic aneurysm stent grafts devices market in the North America region during the forecast period from 2024 to 2030.
